Novartis’ Zolgensma first gene therapy to top $1B 

As the spinal muscular atrophy market continues to grow, Novartis’ Zolgensma has become the first gene therapy to cross the $1 billion mark in annual sales — with a quarter to spare. 

Novartis AG (NYSE:NVS; SIX:NOVN) reported 3Q21 sales of $375 million for Zolgensma onasemnogene abeparvovec-xioi, pushing the gene therapy’s 2021 sales across the blockbuster threshold. The therapy, which Novartis gained through its $8.7 billion acquisition of AveXis Inc. in 2018, had 2020 sales of $920 million...